23 May 2013
Keywords: Capsugel, Pfizer, Kohlber Kravis Roberts, Tafamidis, Amyloid polyneuropathy, FDA, USA
Article | 05 April 2011
In line with recent guidance that it is viewing the sale of some non-core businesses, global drugs behemoth Pfizer (NYSE: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 April 2011
6 April 2011
© 2013 thepharmaletter.com